Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project
Markers of inflammation, such as C-reactive protein (CRP), are related to risk of cardiovascular disease (CVD) events in those with angina, but little is known about individuals without prevalent clinical CVD. We performed a prospective, nested case-control study in the Cardiovascular Health Study (...
Uloženo v:
| Vydáno v: | Arteriosclerosis, thrombosis, and vascular biology Ročník 17; číslo 6; s. 1121 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.06.1997
|
| Témata: | |
| ISSN: | 1079-5642 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Markers of inflammation, such as C-reactive protein (CRP), are related to risk of cardiovascular disease (CVD) events in those with angina, but little is known about individuals without prevalent clinical CVD. We performed a prospective, nested case-control study in the Cardiovascular Health Study (CHS; 5201 healthy elderly men and women). Case subjects (n = 146 men and women with incident CVD events including angina, myocardial infarction, and death) and control subjects (n = 146) were matched on the basis of sex and the presence or absence of significant subclinical CVD at baseline (average follow-up, 2.4 years). In women but not men, the mean CRP level was higher for case subjects than for control subjects (P < or = .05). In general, CRP was higher in those with subclinical disease. Most of the association of CRP with female case subjects versus control subjects was in the subgroup with subclinical disease; 3.33 versus 1.90 mg/L, P < .05, adjusted for age and time of follow-up. Case-control differences were greatest when the time between baseline and the CVD event was shortest. The strongest associations were with myocardial infarction, and there was an overall odds ratio for incident myocardial infarction for men and women with subclinical disease (upper quartile versus lower three quartiles) of 2.67 (confidence interval [CI] = 1.04 to 6.81), with the relationship being stronger in women (4.50 [CI = 0.97 to 20.8]) than in men (1.75 [CI = 0.51 to 5.98]). We performed a similar study in the Rural Health Promotion Project, in which mean values of CRP were higher for female case subjects than for female control subjects, but no differences were apparent for men. Comparing the upper quintile with the lower four, the odds ratio for CVD case subjects was 2.7 (CI = 1.10 to 6.60). In conclusion, CRP was associated with incident events in the elderly, especially in those with subclinical disease at baseline. |
|---|---|
| AbstractList | Markers of inflammation, such as C-reactive protein (CRP), are related to risk of cardiovascular disease (CVD) events in those with angina, but little is known about individuals without prevalent clinical CVD. We performed a prospective, nested case-control study in the Cardiovascular Health Study (CHS; 5201 healthy elderly men and women). Case subjects (n = 146 men and women with incident CVD events including angina, myocardial infarction, and death) and control subjects (n = 146) were matched on the basis of sex and the presence or absence of significant subclinical CVD at baseline (average follow-up, 2.4 years). In women but not men, the mean CRP level was higher for case subjects than for control subjects (P < or = .05). In general, CRP was higher in those with subclinical disease. Most of the association of CRP with female case subjects versus control subjects was in the subgroup with subclinical disease; 3.33 versus 1.90 mg/L, P < .05, adjusted for age and time of follow-up. Case-control differences were greatest when the time between baseline and the CVD event was shortest. The strongest associations were with myocardial infarction, and there was an overall odds ratio for incident myocardial infarction for men and women with subclinical disease (upper quartile versus lower three quartiles) of 2.67 (confidence interval [CI] = 1.04 to 6.81), with the relationship being stronger in women (4.50 [CI = 0.97 to 20.8]) than in men (1.75 [CI = 0.51 to 5.98]). We performed a similar study in the Rural Health Promotion Project, in which mean values of CRP were higher for female case subjects than for female control subjects, but no differences were apparent for men. Comparing the upper quintile with the lower four, the odds ratio for CVD case subjects was 2.7 (CI = 1.10 to 6.60). In conclusion, CRP was associated with incident events in the elderly, especially in those with subclinical disease at baseline.Markers of inflammation, such as C-reactive protein (CRP), are related to risk of cardiovascular disease (CVD) events in those with angina, but little is known about individuals without prevalent clinical CVD. We performed a prospective, nested case-control study in the Cardiovascular Health Study (CHS; 5201 healthy elderly men and women). Case subjects (n = 146 men and women with incident CVD events including angina, myocardial infarction, and death) and control subjects (n = 146) were matched on the basis of sex and the presence or absence of significant subclinical CVD at baseline (average follow-up, 2.4 years). In women but not men, the mean CRP level was higher for case subjects than for control subjects (P < or = .05). In general, CRP was higher in those with subclinical disease. Most of the association of CRP with female case subjects versus control subjects was in the subgroup with subclinical disease; 3.33 versus 1.90 mg/L, P < .05, adjusted for age and time of follow-up. Case-control differences were greatest when the time between baseline and the CVD event was shortest. The strongest associations were with myocardial infarction, and there was an overall odds ratio for incident myocardial infarction for men and women with subclinical disease (upper quartile versus lower three quartiles) of 2.67 (confidence interval [CI] = 1.04 to 6.81), with the relationship being stronger in women (4.50 [CI = 0.97 to 20.8]) than in men (1.75 [CI = 0.51 to 5.98]). We performed a similar study in the Rural Health Promotion Project, in which mean values of CRP were higher for female case subjects than for female control subjects, but no differences were apparent for men. Comparing the upper quintile with the lower four, the odds ratio for CVD case subjects was 2.7 (CI = 1.10 to 6.60). In conclusion, CRP was associated with incident events in the elderly, especially in those with subclinical disease at baseline. Markers of inflammation, such as C-reactive protein (CRP), are related to risk of cardiovascular disease (CVD) events in those with angina, but little is known about individuals without prevalent clinical CVD. We performed a prospective, nested case-control study in the Cardiovascular Health Study (CHS; 5201 healthy elderly men and women). Case subjects (n = 146 men and women with incident CVD events including angina, myocardial infarction, and death) and control subjects (n = 146) were matched on the basis of sex and the presence or absence of significant subclinical CVD at baseline (average follow-up, 2.4 years). In women but not men, the mean CRP level was higher for case subjects than for control subjects (P < or = .05). In general, CRP was higher in those with subclinical disease. Most of the association of CRP with female case subjects versus control subjects was in the subgroup with subclinical disease; 3.33 versus 1.90 mg/L, P < .05, adjusted for age and time of follow-up. Case-control differences were greatest when the time between baseline and the CVD event was shortest. The strongest associations were with myocardial infarction, and there was an overall odds ratio for incident myocardial infarction for men and women with subclinical disease (upper quartile versus lower three quartiles) of 2.67 (confidence interval [CI] = 1.04 to 6.81), with the relationship being stronger in women (4.50 [CI = 0.97 to 20.8]) than in men (1.75 [CI = 0.51 to 5.98]). We performed a similar study in the Rural Health Promotion Project, in which mean values of CRP were higher for female case subjects than for female control subjects, but no differences were apparent for men. Comparing the upper quintile with the lower four, the odds ratio for CVD case subjects was 2.7 (CI = 1.10 to 6.60). In conclusion, CRP was associated with incident events in the elderly, especially in those with subclinical disease at baseline. |
| Author | Ives, D G Meilahn, E N Kuller, L H Lemaitre, R N Psaty, B M Tracy, R P Cushman, M Evans, R W |
| Author_xml | – sequence: 1 givenname: R P surname: Tracy fullname: Tracy, R P email: rtracy@mouse.uvm.edu organization: University of Vermont, Colchester 05446, USA. rtracy@mouse.uvm.edu – sequence: 2 givenname: R N surname: Lemaitre fullname: Lemaitre, R N – sequence: 3 givenname: B M surname: Psaty fullname: Psaty, B M – sequence: 4 givenname: D G surname: Ives fullname: Ives, D G – sequence: 5 givenname: R W surname: Evans fullname: Evans, R W – sequence: 6 givenname: M surname: Cushman fullname: Cushman, M – sequence: 7 givenname: E N surname: Meilahn fullname: Meilahn, E N – sequence: 8 givenname: L H surname: Kuller fullname: Kuller, L H |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/9194763$$D View this record in MEDLINE/PubMed |
| BookMark | eNpVkE1PAjEQhnvAIKB3LyY9edu17X72SDYqJiQaRK-k3c6GYtli2yXhH_kzXRAPXmYm7_vMZGbGaNDaFhC6oSSmNKf3hMbT5UdMizjvBUYHaERJwaMsT9klGnu_IYSkjJEhGnLK0yJPRuh7AUYEbVu_1jtsG1xFDkQd9B7wztkAusXBYqf959GthVPa7oWvOyMcVtqD8ICP0BowGAXOHGK8AN-Z4HHj7PbkVP_7ZiBMWOO30KkDFq06MYvOCfNnvfad9rjXsdpAHa7QRSOMh-tznqD3x4dlNYvmL0_P1XQe1SnjeSQT1ahGAOOZkLLMuGzqRjKeMCkyqbKcpoLkwAuW9DovKQDpY5mSukyopGyC7n7n9td_deDDaqt9DcaIFmznVwUnRUnTpAdvz2Ant6BWO6e3wh1W59eyH_7Ffvs |
| CitedBy_id | crossref_primary_10_1542_peds_107_1_e13 crossref_primary_10_1046_j_1365_2796_2000_00754_x crossref_primary_10_1016_j_diabres_2004_05_009 crossref_primary_10_1093_eurheartj_ehz961 crossref_primary_10_1016_j_pcad_2007_11_003 crossref_primary_10_3390_cancers12061698 crossref_primary_10_1016_j_atherosclerosis_2008_04_012 crossref_primary_10_1016_S0006_3223_02_01811_5 crossref_primary_10_1016_j_lab_2005_03_009 crossref_primary_10_1309_AA7V_PRPU_CE90_UF36 crossref_primary_10_1089_jmf_2022_0100 crossref_primary_10_1155_2010_792393 crossref_primary_10_1038_sj_jhh_1001537 crossref_primary_10_1007_s12170_012_0262_0 crossref_primary_10_1097_00075198_200310000_00006 crossref_primary_10_3889_oamjms_2022_9924 crossref_primary_10_1016_j_atherosclerosis_2008_12_022 crossref_primary_10_1016_j_atherosclerosis_2014_09_012 crossref_primary_10_1016_S0021_9150_98_00284_6 crossref_primary_10_1046_j_1525_139X_2003_16031_x crossref_primary_10_1007_s11746_006_5153_4 crossref_primary_10_1093_clinchem_46_10_1597 crossref_primary_10_1097_00041433_200108000_00005 crossref_primary_10_1016_S0025_7125_05_70211_X crossref_primary_10_1016_j_clinbiochem_2010_09_016 crossref_primary_10_1038_sj_ijo_0801792 crossref_primary_10_1002_ana_10265 crossref_primary_10_1111_j_1365_2036_2006_00026_x crossref_primary_10_1515_CCLM_2007_279 crossref_primary_10_1111_j_1447_0594_2006_00348_x crossref_primary_10_1016_S0002_9343_99_00027_3 crossref_primary_10_3390_jcm11030706 crossref_primary_10_4103_jiaomr_jiaomr_233_24 crossref_primary_10_1161_ATVBAHA_111_232348 crossref_primary_10_1016_j_jvs_2010_02_004 crossref_primary_10_1373_clinchem_2008_115923 crossref_primary_10_1258_jms_2009_009087 crossref_primary_10_1038_sj_jhh_1001878 crossref_primary_10_1016_j_jim_2008_03_009 crossref_primary_10_1111_j_1741_2358_2003_00032_x crossref_primary_10_1111_j_1365_2796_2008_02015_x crossref_primary_10_1111_jth_13111 crossref_primary_10_1186_1758_3284_2_21 crossref_primary_10_3390_ijms22084033 crossref_primary_10_1093_clinchem_47_1_28 crossref_primary_10_1089_154041903321648252 crossref_primary_10_1046_j_1464_5491_2002_00770_x crossref_primary_10_35371_aoem_2019_31_e5 crossref_primary_10_1002_tox_23394 crossref_primary_10_1016_j_cca_2010_06_003 crossref_primary_10_1111_j_1365_2796_2004_01415_x crossref_primary_10_3945_jn_115_218016 crossref_primary_10_2337_diacare_29_02_06_dc05_1700 crossref_primary_10_1016_j_ijcard_2004_05_019 crossref_primary_10_1007_s10654_007_9121_6 crossref_primary_10_1182_blood_2004_12_4971 crossref_primary_10_1016_j_arr_2016_01_007 crossref_primary_10_1080_07315724_2007_10719584 crossref_primary_10_3390_microorganisms13010185 crossref_primary_10_1016_j_atherosclerosissup_2005_02_005 crossref_primary_10_1016_S0015_0282_02_03078_9 crossref_primary_10_1016_j_ctim_2018_12_005 crossref_primary_10_1007_s11883_003_0004_3 crossref_primary_10_1007_s00404_008_0712_6 crossref_primary_10_4158_EP_6_3_272 crossref_primary_10_1016_j_maturitas_2004_02_016 crossref_primary_10_1038_oby_2006_41 crossref_primary_10_1097_00001648_200209000_00012 crossref_primary_10_1177_1358863X15617541 crossref_primary_10_1002_sim_6231 crossref_primary_10_1111_j_1532_5415_2004_52307_x crossref_primary_10_1016_j_bmc_2012_06_032 crossref_primary_10_1161_HYPERTENSIONAHA_109_148007 crossref_primary_10_1016_j_mcna_2004_04_016 crossref_primary_10_1016_j_dsx_2019_01_041 crossref_primary_10_1016_S0002_9343_02_01497_3 crossref_primary_10_1291_hypres_27_955 crossref_primary_10_1186_s12881_019_0910_z crossref_primary_10_1016_S1889_1837_03_71352_X crossref_primary_10_1016_j_ijcard_2013_07_109 crossref_primary_10_1002_rth2_12038 crossref_primary_10_1080_10408360290795556 crossref_primary_10_1016_S1262_3636_07_70019_8 crossref_primary_10_1016_j_diabres_2003_10_007 crossref_primary_10_3892_etm_2014_1673 crossref_primary_10_1016_j_cca_2005_12_027 crossref_primary_10_1155_2013_678159 crossref_primary_10_3390_biom12040492 crossref_primary_10_1016_j_exger_2015_06_005 crossref_primary_10_1177_1358836X0100600304 crossref_primary_10_1054_fipr_1999_0037 crossref_primary_10_1016_j_jacl_2011_07_005 crossref_primary_10_1007_s12170_013_0372_3 crossref_primary_10_1067_mhj_2002_119766 crossref_primary_10_1371_journal_pone_0077655 crossref_primary_10_1007_s11936_019_0753_0 crossref_primary_10_1016_j_pop_2006_09_006 crossref_primary_10_1016_S1262_3636_07_70009_5 crossref_primary_10_1016_j_amjcard_2020_01_005 crossref_primary_10_1111_j_1532_5415_2004_52308_x crossref_primary_10_2337_dc05_2327 crossref_primary_10_4065_80_2_219 crossref_primary_10_1081_AL_200045139 crossref_primary_10_1177_039139880002300301 crossref_primary_10_1177_000331970605700305 crossref_primary_10_1177_000331970605700306 crossref_primary_10_1016_j_amjmed_2004_03_039 crossref_primary_10_1186_1471_2458_10_429 crossref_primary_10_1002_clc_4960261508 crossref_primary_10_1007_s11906_005_0075_3 crossref_primary_10_1016_j_fertnstert_2003_11_033 crossref_primary_10_1016_S0003_4975_98_00973_4 crossref_primary_10_1080_17512433_2018_1425138 crossref_primary_10_1016_j_jvs_2008_07_081 crossref_primary_10_1016_S0021_9150_00_00586_4 crossref_primary_10_1016_S0735_1097_03_00163_3 crossref_primary_10_1016_S0002_9149_99_00491_9 crossref_primary_10_1016_j_ahj_2004_12_032 crossref_primary_10_1016_j_ahj_2004_12_031 crossref_primary_10_1016_S1885_5857_06_60174_6 crossref_primary_10_1097_01_nrl_0000215789_70804_b0 crossref_primary_10_1023_A_1008956327032 crossref_primary_10_1177_2040622316658459 crossref_primary_10_1016_j_phanu_2016_02_001 crossref_primary_10_1016_j_diabres_2005_05_003 crossref_primary_10_1210_er_2002_0034 crossref_primary_10_1016_j_metabol_2005_07_015 crossref_primary_10_1093_aje_kwt086 crossref_primary_10_1007_s10865_011_9345_5 crossref_primary_10_2337_diabetes_53_4_1068 crossref_primary_10_1097_01_CRD_0000077906_74217_6E crossref_primary_10_1212_WNL_0b013e3181bd10bc crossref_primary_10_1111_j_1532_5415_2009_02625_x crossref_primary_10_1081_ERC_200033541 crossref_primary_10_1016_j_vaccine_2004_05_035 crossref_primary_10_1371_journal_pone_0121947 crossref_primary_10_1002_clc_4960251005 crossref_primary_10_1186_1471_2369_14_134 crossref_primary_10_1093_ije_31_6_1129 crossref_primary_10_1210_jcem_87_4_8364 crossref_primary_10_1378_chest_123_2_387 crossref_primary_10_1016_j_cpcardiol_2004_03_004 crossref_primary_10_1016_S0378_5122_03_00217_2 crossref_primary_10_1161_JAHA_119_014070 crossref_primary_10_1016_S0002_9149_01_01603_4 crossref_primary_10_2147_nano_2006_1_2_129 crossref_primary_10_1016_j_annepidem_2006_02_007 crossref_primary_10_1097_MBC_0b013e32832a5fd1 crossref_primary_10_1016_j_ypmed_2004_07_010 crossref_primary_10_1016_j_numecd_2005_11_012 crossref_primary_10_1097_01_fjc_0000211743_93701_eb crossref_primary_10_1136_bmjopen_2021_054638 crossref_primary_10_1046_j_1365_2249_2000_01281_x crossref_primary_10_2215_CJN_02220409 crossref_primary_10_1186_s40168_017_0296_0 crossref_primary_10_1016_j_ijcard_2005_03_044 crossref_primary_10_1046_j_1532_5415_2001_4930254_x crossref_primary_10_1210_edrv_22_1_0417 crossref_primary_10_1111_j_1365_2362_2010_02360_x crossref_primary_10_1016_S1474_4422_05_70099_5 crossref_primary_10_1016_j_ijcard_2007_11_085 crossref_primary_10_1007_s11883_006_0012_1 crossref_primary_10_1093_ntr_ntx230 crossref_primary_10_1037_0033_2909_132_3_327 crossref_primary_10_1016_j_cca_2005_09_007 crossref_primary_10_1016_S0955_2863_02_00187_0 crossref_primary_10_1097_00132580_200109000_00009 crossref_primary_10_1016_j_ypmed_2005_02_002 crossref_primary_10_1046_j_1538_7836_2003_00392_x crossref_primary_10_1093_clinchem_47_3_444 crossref_primary_10_1038_ijo_2013_95 crossref_primary_10_1111_j_1749_6632_2001_tb04014_x crossref_primary_10_1016_S0149_2918_03_80242_4 crossref_primary_10_1007_s11892_003_0072_3 crossref_primary_10_1038_sj_ijo_0802386 crossref_primary_10_1177_117727190800300001 crossref_primary_10_1161_CIRCGENETICS_110_957431 crossref_primary_10_1093_clinchem_45_11_1967 crossref_primary_10_1038_sj_ijo_0802260 crossref_primary_10_1017_S204017441200027X crossref_primary_10_3390_nu17091454 crossref_primary_10_1161_JAHA_113_000651 crossref_primary_10_1097_00000441_200605000_00005 crossref_primary_10_1016_S0268_9499_98_80388_3 crossref_primary_10_1590_S0102_311X2003000700002 crossref_primary_10_7189_jogh_15_04131 crossref_primary_10_1097_00001573_199903000_00016 crossref_primary_10_1016_j_orcp_2015_10_012 crossref_primary_10_1038_sj_ejcn_1601459 crossref_primary_10_1038_sj_ijo_0802274 crossref_primary_10_1016_j_metabol_2004_06_010 crossref_primary_10_1016_S0009_8981_99_00236_3 crossref_primary_10_1016_j_cct_2014_03_009 crossref_primary_10_5665_sleep_2644 crossref_primary_10_1016_S0002_9440_10_64051_5 crossref_primary_10_1016_j_clinbiochem_2006_05_007 crossref_primary_10_1089_met_2010_0115 crossref_primary_10_1186_1479_5876_10_S1_S5 crossref_primary_10_1007_s10654_006_9034_9 crossref_primary_10_1046_j_1464_5491_2003_01030_x crossref_primary_10_1016_j_jvs_2005_03_060 crossref_primary_10_2337_diabetes_50_10_2384 crossref_primary_10_1016_j_atherosclerosis_2008_07_040 crossref_primary_10_1016_j_psychres_2015_06_009 crossref_primary_10_1111_j_1749_6632_2001_tb04015_x crossref_primary_10_1111_j_1532_5415_2000_tb02643_x crossref_primary_10_1016_S0733_8651_03_00079_1 crossref_primary_10_1002_1529_0131_200112_44_12_2737__AID_ART460_3_0_CO_2 crossref_primary_10_1016_S0895_4356_99_00143_2 crossref_primary_10_1373_clinchem_2008_105403 crossref_primary_10_3389_fpsyt_2019_00605 crossref_primary_10_1016_S0021_9150_01_00602_5 crossref_primary_10_1093_clinchem_47_3_418 crossref_primary_10_1016_j_amjcard_2016_08_069 crossref_primary_10_1093_toxsci_kfx095 crossref_primary_10_1291_hypres_30_1177 crossref_primary_10_1093_clinchem_45_12_2136 crossref_primary_10_1016_S0531_5131_03_00143_2 crossref_primary_10_1079_PNS2003328 crossref_primary_10_1046_j_1365_2796_2000_00604_x crossref_primary_10_1074_jbc_M606279200 crossref_primary_10_1016_S0002_9343_02_01209_3 crossref_primary_10_1016_S0895_4356_02_00519_X crossref_primary_10_1093_clinchem_47_3_403 crossref_primary_10_1016_j_jada_2003_12_022 crossref_primary_10_1093_eurheartj_ehn049 crossref_primary_10_1016_S0002_9149_02_03175_2 crossref_primary_10_1111_j_1532_5415_1999_tb01583_x crossref_primary_10_1001_jamanetworkopen_2022_5012 crossref_primary_10_1093_clinchem_46_4_461 crossref_primary_10_1177_147323001003800207 crossref_primary_10_3389_fnagi_2021_669490 crossref_primary_10_1016_j_amjcard_2007_01_036 crossref_primary_10_1177_2040622311399145 crossref_primary_10_1016_S0009_8981_02_00013_X crossref_primary_10_1016_S0735_1097_03_00243_2 crossref_primary_10_1080_00335510500429821 crossref_primary_10_1080_01443610400007810 crossref_primary_10_1016_j_atherosclerosis_2008_08_039 crossref_primary_10_1210_clinem_dgae669 crossref_primary_10_1016_S0735_1097_00_00680_X crossref_primary_10_1093_ndt_gfh680 crossref_primary_10_1586_17446651_2015_1054808 crossref_primary_10_1016_S0002_9149_03_00718_5 crossref_primary_10_1097_MAJ_0b013e3181b9147f crossref_primary_10_1016_S0735_1097_01_01554_6 crossref_primary_10_1097_00041433_199910000_00008 crossref_primary_10_1016_j_amjcard_2007_01_022 crossref_primary_10_1080_07315724_2004_10719354 crossref_primary_10_1097_INF_0000000000001352 crossref_primary_10_3892_etm_2016_3882 crossref_primary_10_1155_2014_613157 crossref_primary_10_1177_000331970205300304 crossref_primary_10_2337_dc13_2059 crossref_primary_10_1002_clc_20830 crossref_primary_10_1080_10641960701578394 crossref_primary_10_1016_j_bbi_2008_05_011 crossref_primary_10_1097_01_psy_0000130963_52755_b9 crossref_primary_10_1002_1529_0131_199901_42_1_51__AID_ANR7_3_0_CO_2_D crossref_primary_10_1097_00041433_200010000_00010 crossref_primary_10_1111_j_1520_037X_2005_02779_x crossref_primary_10_1111_j_1749_6632_2009_05341_x crossref_primary_10_1007_s11906_014_0502_4 crossref_primary_10_1016_S0264_410X_98_00234_5 crossref_primary_10_1016_j_ijcard_2003_08_016 crossref_primary_10_1097_00041433_200208000_00005 crossref_primary_10_1177_0164027511415245 crossref_primary_10_1177_0003319707304943 crossref_primary_10_1016_S0735_1097_02_02953_4 crossref_primary_10_1373_clinchem_2003_027359 crossref_primary_10_1016_S0735_1097_00_00582_9 crossref_primary_10_1016_j_neuint_2017_02_009 crossref_primary_10_1093_hmg_ddu450 crossref_primary_10_1016_S0002_9343_03_00074_3 crossref_primary_10_1515_CCLM_1999_080 crossref_primary_10_1177_0891988709351832 crossref_primary_10_1080_09273948_2023_2203742 crossref_primary_10_1046_j_1365_2796_2000_00670_x crossref_primary_10_1586_14737175_4_3_507 crossref_primary_10_1016_S0022_3999_01_00302_6 crossref_primary_10_1016_S0002_9343_99_00066_2 crossref_primary_10_1046_j_1365_2796_2002_01019_x crossref_primary_10_1053_j_ajkd_2009_01_261 crossref_primary_10_1097_MED_0b013e3282f7cd6d crossref_primary_10_1007_s11886_000_0080_8 crossref_primary_10_1080_07315724_2012_10720018 crossref_primary_10_1373_49_4_686 crossref_primary_10_1111_1753_0407_12538 crossref_primary_10_1016_j_jacl_2007_10_008 crossref_primary_10_1016_j_atherosclerosis_2006_11_002 crossref_primary_10_1097_HJH_0b013e328011753e crossref_primary_10_1016_S0002_9149_02_02419_0 crossref_primary_10_1515_CCLM_2002_011 crossref_primary_10_1016_j_diabres_2005_03_025 crossref_primary_10_1053_pcad_2002_123782 crossref_primary_10_1186_s13098_025_01609_8 crossref_primary_10_1016_j_jpeds_2004_11_033 crossref_primary_10_1345_aph_1D203 crossref_primary_10_1016_j_atherosclerosis_2004_07_033 crossref_primary_10_1067_mhj_2003_16 crossref_primary_10_1515_CCLM_2003_029 crossref_primary_10_1016_S0026_0495_03_00184_7 crossref_primary_10_1016_S1535_5535_04_00151_0 crossref_primary_10_1016_j_ehj_2014_11_005 crossref_primary_10_1056_NEJMoa032804 crossref_primary_10_1186_2251_6581_13_64 crossref_primary_10_1016_j_gheart_2014_11_004 crossref_primary_10_1007_s11886_000_0081_7 crossref_primary_10_1016_S0021_9150_98_90209_X crossref_primary_10_1046_j_1529_8817_2004_00078_x crossref_primary_10_1017_S0007114520003591 crossref_primary_10_1016_j_ahj_2022_07_001 crossref_primary_10_1053_meta_2003_50001 crossref_primary_10_1007_s11883_002_0019_1 crossref_primary_10_1111_1440_1681_12758 crossref_primary_10_1016_j_ahj_2005_02_002 crossref_primary_10_1093_ajcn_75_3_492 crossref_primary_10_1016_j_imlet_2016_12_004 crossref_primary_10_1007_s11883_999_0039_1 crossref_primary_10_1111_jre_12172 crossref_primary_10_1080_20014091084245 crossref_primary_10_1186_1475_2840_6_10 crossref_primary_10_1016_S0268_9499_97_80040_9 crossref_primary_10_1046_j_1523_1755_2001_59780032_x crossref_primary_10_1023_B_JOCI_0000010423_65719_e5 crossref_primary_10_1038_jhh_2011_113 crossref_primary_10_1111_jth_13899 crossref_primary_10_1111_j_1523_1755_2005_00455_x crossref_primary_10_1016_S0149_2918_03_80195_9 crossref_primary_10_1016_j_ihj_2023_10_007 crossref_primary_10_1007_s00404_009_1292_9 crossref_primary_10_3109_07853890108995963 crossref_primary_10_1016_j_ijcard_2005_06_021 crossref_primary_10_4103_jpbs_jpbs_845_21 crossref_primary_10_1111_j_1365_2362_2005_01574_x crossref_primary_10_1016_j_ijcard_2003_10_027 crossref_primary_10_1016_j_arr_2010_11_002 crossref_primary_10_1016_j_exger_2016_03_002 crossref_primary_10_1002_art_20630 crossref_primary_10_1016_S0002_9343_03_00238_9 crossref_primary_10_1056_NEJM200003233421202 crossref_primary_10_1016_j_anai_2010_04_004 crossref_primary_10_1016_j_ddmec_2004_08_001 crossref_primary_10_1155_2014_605810 crossref_primary_10_1053_j_ajkd_2005_03_008 crossref_primary_10_2147_vhrm_2006_2_3_221 crossref_primary_10_1016_S0009_8981_01_00797_5 crossref_primary_10_1016_j_metabol_2004_10_010 crossref_primary_10_1186_1475_2840_13_38 crossref_primary_10_1016_j_metabol_2004_01_003 crossref_primary_10_1016_j_jsha_2012_06_260 crossref_primary_10_1067_mhj_2002_124353 crossref_primary_10_1007_s12170_008_0079_z crossref_primary_10_1515_CCLM_2002_146 crossref_primary_10_1038_sj_ijo_0801719 crossref_primary_10_1023_B_THRO_0000014601_57424_b8 crossref_primary_10_1016_j_ijcard_2004_12_051 crossref_primary_10_1067_mhj_2001_115297 crossref_primary_10_1210_jcem_85_1_6326 crossref_primary_10_1097_01_ccx_0000244119_16377_75 crossref_primary_10_1007_s40520_019_01222_6 crossref_primary_10_1016_j_metabol_2005_11_002 crossref_primary_10_1111_jre_12380 crossref_primary_10_1080_09553002_2017_1325971 crossref_primary_10_1002_jcla_23470 crossref_primary_10_1016_j_amjopharm_2007_03_008 crossref_primary_10_1016_j_diabres_2006_04_019 crossref_primary_10_1016_S0735_1097_00_00952_9 crossref_primary_10_1016_j_nutres_2018_03_004 crossref_primary_10_1359_jbmr_070409 crossref_primary_10_1016_S1728_869X_09_60012_5 crossref_primary_10_2337_db06_0880 crossref_primary_10_1016_j_jim_2006_01_020 crossref_primary_10_1038_ajh_2011_192 crossref_primary_10_1016_j_ahj_2017_02_035 crossref_primary_10_1016_j_ijcard_2004_12_064 crossref_primary_10_1097_01_PSY_0000041542_29808_01 crossref_primary_10_1016_j_atherosclerosissup_2006_01_004 crossref_primary_10_1016_j_jvs_2012_01_059 crossref_primary_10_1067_mhj_2002_124054 crossref_primary_10_1097_00004872_200310000_00002 crossref_primary_10_1016_S0009_9120_00_00186_7 crossref_primary_10_1086_315628 crossref_primary_10_1016_S0955_2863_03_00101_3 crossref_primary_10_1189_jlb_0505241 crossref_primary_10_1097_01_psy_0000208630_79271_a0 crossref_primary_10_1016_j_atherosclerosis_2006_09_027 crossref_primary_10_1016_j_cmet_2020_01_009 crossref_primary_10_1016_j_atherosclerosis_2008_04_045 crossref_primary_10_1016_S1047_2797_03_00053_X crossref_primary_10_1016_j_jamda_2013_05_009 crossref_primary_10_1111_ijs_12216 crossref_primary_10_1016_S0049_3848_99_00237_6 crossref_primary_10_1093_clinchem_48_2_269 crossref_primary_10_1016_S0002_9343_03_00183_9 crossref_primary_10_1002_jcla_23259 crossref_primary_10_1111_jch_12116 crossref_primary_10_4103_2277_8632_178941 crossref_primary_10_1034_j_1600_0854_2003_8025_x crossref_primary_10_1056_NEJMoa021993 crossref_primary_10_1136_hrt_2006_088211 crossref_primary_10_1016_j_amjmed_2005_10_060 crossref_primary_10_1177_1076029612459675 crossref_primary_10_1016_S0953_6205_03_00099_2 crossref_primary_10_1016_S0306_9877_02_00232_3 crossref_primary_10_1111_j_1520_037X_2002_1032_x crossref_primary_10_1111_j_0889_7204_2000_080398_x crossref_primary_10_1111_j_1749_6632_2001_tb04031_x crossref_primary_10_1080_07435800500229268 crossref_primary_10_1515_CCLM_2001_171 crossref_primary_10_1046_j_1523_1755_2000_00331_x crossref_primary_10_1067_mhj_2001_109951 crossref_primary_10_1177_0003319707309119 crossref_primary_10_1016_j_amjmed_2005_10_062 crossref_primary_10_1016_j_jdiacomp_2006_10_004 crossref_primary_10_1371_journal_pone_0261312 crossref_primary_10_1016_S0002_9149_03_00774_4 crossref_primary_10_1016_S0895_4356_01_00502_9 crossref_primary_10_1016_S0009_9120_01_00227_2 crossref_primary_10_1111_j_1368_5031_2005_00428_x crossref_primary_10_1093_ehjqcco_qcv028 crossref_primary_10_1080_07435800500229151 crossref_primary_10_2478_amtsb_2020_0005 crossref_primary_10_1038_oby_2005_220 crossref_primary_10_1111_j_1753_4887_2007_tb00369_x crossref_primary_10_1056_NEJM200008173430715 crossref_primary_10_3109_14767058_2010_511340 crossref_primary_10_1016_j_cca_2012_06_004 crossref_primary_10_1016_j_amjcard_2007_11_006 crossref_primary_10_1586_eem_09_44 crossref_primary_10_3390_immuno2020021 crossref_primary_10_1016_j_arr_2020_101093 crossref_primary_10_1155_2012_606207 crossref_primary_10_1016_j_ijcard_2005_11_110 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1161/01.ATV.17.6.1121 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| ExternalDocumentID | 9194763 |
| Genre | Multicenter Study Research Support, U.S. Gov't, P.H.S Journal Article |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: N01-HC-85086 – fundername: NHLBI NIH HHS grantid: R01 HL-46696 – fundername: NHLBI NIH HHS grantid: N01-HC-85079 |
| GroupedDBID | --- .3C .55 .GJ .Z2 01R 0R~ 1J1 23N 2WC 3O- 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AARTV AASCR AASOK AAXQO ABASU ABBUW ABDIG ABJNI ABQRW ABVCZ ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFS ACGOD ACIJW ACILI ACLDA ACPRK ACWDW ACWRI ACXJB ACXNZ ADBBV ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFDTB AFFNX AFUWQ AGINI AHJKT AHMBA AHOMT AHQNM AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM AYCSE BAWUL BOYCO BQLVK BS7 C1A C45 CGR CS3 CUY CVF DIK DIWNM DUNZO E.X E3Z EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FRP FW0 GNXGY GQDEL GX1 H0~ H13 HLJTE HZ~ IKREB IKYAY IN~ IPNFZ J5H JF9 JG8 JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N9A NPM N~7 N~B N~M O9- OAG OAH OB2 OCUKA ODA OK1 OL1 OLG OLH OLU OLV OLW OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ PZZ RAH RHF RIG RLZ S4R S4S T8P TEORI TR2 TSPGW V2I VVN W3M W8F WOQ WOW X3V X3W X7M XXN XYM YFH ZGI ZZMQN 7X8 ABPXF ACZKN ADGHP ADKSD |
| ID | FETCH-LOGICAL-c4296-b3dfdfae295abb859bfcfb2932ba5bd5614a06e9723cfb981ee0981840c831b12 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 699 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00043605-199706000-00016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1079-5642 |
| IngestDate | Mon Sep 08 13:38:19 EDT 2025 Wed Feb 19 02:33:08 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4296-b3dfdfae295abb859bfcfb2932ba5bd5614a06e9723cfb981ee0981840c831b12 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 9194763 |
| PQID | 79078143 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_79078143 pubmed_primary_9194763 |
| PublicationCentury | 1900 |
| PublicationDate | 1997-June |
| PublicationDateYYYYMMDD | 1997-06-01 |
| PublicationDate_xml | – month: 06 year: 1997 text: 1997-June |
| PublicationDecade | 1990 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Arteriosclerosis, thrombosis, and vascular biology |
| PublicationTitleAlternate | Arterioscler Thromb Vasc Biol |
| PublicationYear | 1997 |
| SSID | ssj0004220 |
| Score | 2.156257 |
| Snippet | Markers of inflammation, such as C-reactive protein (CRP), are related to risk of cardiovascular disease (CVD) events in those with angina, but little is known... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1121 |
| SubjectTerms | Aged Aging C-Reactive Protein - metabolism Cardiovascular Diseases - blood Case-Control Studies Female Humans Male Prospective Studies Sex Factors |
| Title | Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/9194763 https://www.proquest.com/docview/79078143 |
| Volume | 17 |
| WOSCitedRecordID | wos00043605-199706000-00016&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA7VinjxXazPHLxuu9lHswFBpFi8tJSi0NuS19JC2a32Af1H_kxn9iH2IB7cQ1g2CSzMZPIlM_MNIfcqCJXSAiRgFHcCAUtRCqsAyDEujXUBxOq82AQfDKLxWAxr5KHKhcGwysom5obaZBrvyNtcIC1N4D_O3x2sGYW-1bKAxg6p-wBkUKf5-AdXuOcVXARcOCHA7MpJ2WFtl4Ew1i3GWx3MoWG_w8t8m-kd_e8Hj8lhCS_pU6EPJ6Rm01Oy3y8d6Gfk8zv4bTKd0yyhXQdQY27zaE7ZME3pMqMYcI69eitalZbeHIqDJpZarPA927ToyC5Ws-WCYq5K3tPdnlfkOlGMWdxQmZp8zAgJP6quYREVmKX4hldD5-St9_zafXHKYg2Ohi2t4yjfJCaR1hOhVCoKhUp0ogBMeEqGyiDhqHQ7FoucwXcRMWtdaOF8qSOfKeY1yG6apfaCUDcyHB8b-Qloj5KGw8FQGzgLKhYmUZPcVRKIYTGgh0OmNlst4koGTdIohBjPC86OWDARgCm9_HPqFTkoGGrxouWa1BOwAvaG7On1crr4uM1VDNrBsP8FuB_fUQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relationship+of+C-reactive+protein+to+risk+of+cardiovascular+disease+in+the+elderly.+Results+from+the+Cardiovascular+Health+Study+and+the+Rural+Health+Promotion+Project&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Tracy%2C+R+P&rft.au=Lemaitre%2C+R+N&rft.au=Psaty%2C+B+M&rft.au=Ives%2C+D+G&rft.date=1997-06-01&rft.issn=1079-5642&rft.volume=17&rft.issue=6&rft.spage=1121&rft_id=info:doi/10.1161%2F01.atv.17.6.1121&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon |